<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 13 Jun 2021 07:18:08 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>医药笔记文章合集</title><link>https://mp.weixin.qq.com/s/5KEd4Af0yHctzuW1ZWFqtA</link><description></description><content:encoded><![CDATA[医药笔记文章合集]]></content:encoded><pubDate>Sun, 13 Jun 2021 07:00:34 +0800</pubDate></item><item><title>中国ADC竞争格局</title><link>https://mp.weixin.qq.com/s/h9D2dZzfVjGupmCfvTd2oA</link><description></description><content:encoded><![CDATA[中国ADC竞争格局]]></content:encoded><pubDate>Sat, 12 Jun 2021 06:13:12 +0800</pubDate></item><item><title>豪森药业大分子管线布局</title><link>https://mp.weixin.qq.com/s/WnQMgGgObcLyXi--5BAXNg</link><description></description><content:encoded><![CDATA[豪森药业大分子管线布局]]></content:encoded><pubDate>Fri, 11 Jun 2021 06:50:54 +0800</pubDate></item><item><title>王旭宇出任赛多利斯生物工艺解决方案中国区负责人</title><link>https://mp.weixin.qq.com/s/iCeJDeZbPGrMklxK9AFZoA</link><description></description><content:encoded><![CDATA[王旭宇出任赛多利斯生物工艺解决方案中国区负责人]]></content:encoded><pubDate>Fri, 11 Jun 2021 06:50:54 +0800</pubDate></item><item><title>4500万美元预付款：百济神州引进异体NK细胞疗法</title><link>https://mp.weixin.qq.com/s/L-nMyEEdKFxqkRA8KPmKyw</link><description></description><content:encoded><![CDATA[4500万美元预付款：百济神州引进异体NK细胞疗法]]></content:encoded><pubDate>Thu, 10 Jun 2021 06:09:10 +0800</pubDate></item><item><title>和元生物科创板IPO，基因治疗CDMO爆发增长</title><link>https://mp.weixin.qq.com/s/94JrAj4exeMoCJCGcndSNg</link><description></description><content:encoded><![CDATA[和元生物科创板IPO，基因治疗CDMO爆发增长]]></content:encoded><pubDate>Wed, 09 Jun 2021 07:58:36 +0800</pubDate></item><item><title>国内首个！乐普生物TF ADC提交中国新药临床申请</title><link>https://mp.weixin.qq.com/s/mdBRdhoSgnCCoQb0KFF-BQ</link><description></description><content:encoded><![CDATA[国内首个！乐普生物TF ADC提交中国新药临床申请]]></content:encoded><pubDate>Wed, 09 Jun 2021 07:58:36 +0800</pubDate></item><item><title>ASCO：跨国药企看点</title><link>https://mp.weixin.qq.com/s/DMldd4or9swuvKRVdKAj9g</link><description></description><content:encoded><![CDATA[ASCO：跨国药企看点]]></content:encoded><pubDate>Wed, 09 Jun 2021 07:58:36 +0800</pubDate></item><item><title>亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂前景无限</title><link>https://mp.weixin.qq.com/s/dtGouCxDWCfsZkXwrBKS7w</link><description></description><content:encoded><![CDATA[亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂前景无限]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>Moderna 偏向性IL-2 mRNA启动临床研究</title><link>https://mp.weixin.qq.com/s/6wr9qpg7MwQ9SkWdupP-6g</link><description></description><content:encoded><![CDATA[Moderna 偏向性IL-2 mRNA启动临床研究]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>国内首家：健信生物申报PD-1/TIM-3双抗</title><link>https://mp.weixin.qq.com/s/uedxEvAS2Q1pBJ06ENd-xw</link><description></description><content:encoded><![CDATA[国内首家：健信生物申报PD-1/TIM-3双抗]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>Nature：纳米抗体攻克新冠突变体</title><link>https://mp.weixin.qq.com/s/-FcFdNqUxsIR65GJu1tWjw</link><description></description><content:encoded><![CDATA[Nature：纳米抗体攻克新冠突变体]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>Nature：癌症细胞疗法统计</title><link>https://mp.weixin.qq.com/s/YwA2twoAbQAtuHOo6a-Bmw</link><description></description><content:encoded><![CDATA[Nature：癌症细胞疗法统计]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>Nature：癌症细胞因子疗法全景图</title><link>https://mp.weixin.qq.com/s/7825zNA6xz7zTkC7ip6yNA</link><description></description><content:encoded><![CDATA[Nature：癌症细胞因子疗法全景图]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>乐普生物差异化PD-1单抗，临床优势初显</title><link>https://mp.weixin.qq.com/s/KntbXNNM1_5yoInPVwHm2Q</link><description></description><content:encoded><![CDATA[乐普生物差异化PD-1单抗，临床优势初显]]></content:encoded><pubDate>Mon, 07 Jun 2021 06:56:04 +0800</pubDate></item><item><title>ASCO：鱼叉断</title><link>https://mp.weixin.qq.com/s/AIQ4P-K2xosTvEOD8K_Jug</link><description></description><content:encoded><![CDATA[ASCO：鱼叉断]]></content:encoded><pubDate>Sat, 05 Jun 2021 06:41:20 +0800</pubDate></item><item><title>索马鲁肽获FDA批准治疗肥胖症</title><link>https://mp.weixin.qq.com/s/SqunFmLSwrq1OxZ4QwAg_Q</link><description></description><content:encoded><![CDATA[索马鲁肽获FDA批准治疗肥胖症]]></content:encoded><pubDate>Sat, 05 Jun 2021 06:41:20 +0800</pubDate></item><item><title>荣昌生物即将申报Claudin 18.2 ADC</title><link>https://mp.weixin.qq.com/s/B8V7JSxyGZUA-52DaCnTpQ</link><description></description><content:encoded><![CDATA[荣昌生物即将申报Claudin 18.2 ADC]]></content:encoded><pubDate>Sat, 05 Jun 2021 06:41:20 +0800</pubDate></item><item><title>岸迈生物研发PD-L1/TGFβ双抗</title><link>https://mp.weixin.qq.com/s/QynXlovSmsgudMJT4vTgMw</link><description></description><content:encoded><![CDATA[岸迈生物研发PD-L1/TGFβ双抗]]></content:encoded><pubDate>Fri, 04 Jun 2021 09:12:07 +0800</pubDate></item><item><title>恒瑞医药一季度营收69亿元，增幅25%</title><link>https://mp.weixin.qq.com/s/u1foiRLCFAIYKxJUmsXhww</link><description></description><content:encoded><![CDATA[恒瑞医药一季度营收69亿元，增幅25%]]></content:encoded><pubDate>Fri, 04 Jun 2021 09:12:07 +0800</pubDate></item></channel></rss>